Biopharmaceutical News and Research

RSS

CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea, Neisseria gonorrhoeae (NG), and its susceptibility to ciprofloxacin, a former frontline oral antibiotic that can no longer treat resistant NG.

9 Feb 2024

Enterprise Therapeutics closes £26 million ($33.1 million) Series B follow-on financing

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

From Enterprise Therapeutics Ltd 31 Jan 2024

Balancing efficacy and safety: The challenges of mRNA drugs and vaccines in modern medicine

Researchers analyzed the toxicity concerns and advancements in mRNA therapeutics, focusing on their cellular toxicity, reactogenicity, and distribution, and discussed the challenges and benefits of mRNA research.

24 Jan 2024

New blood test technique raises hopes for more sensitive and earlier cancer diagnosis

Tumors constantly shed DNA from dying cells, which briefly circulates in the patient's bloodstream before it is quickly broken down. Many companies have created blood tests that can pick out this tumor DNA, potentially helping doctors diagnose or monitor cancer or choose a treatment.

18 Jan 2024

£30M clinical study will enhance the understanding of NASH cirrhosis

The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and leading research-driven global biopharmaceutical company, Boehringer Ingelheim.

8 Jan 2024

Scripps Research commemorates 100 years of innovation in science and medicine

Scripps Research, a nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation, will celebrate its 100-year history throughout 2024.

5 Jan 2024

Bridging ideas to IND: Nona Biosciences' year of impact in biotechnology

Amidst a backdrop of industry-wide hurdles like inflation, talent scarcities, and stringent regulatory landscapes, Nona Biosciences is showing great promise as an emerging global leader in biotechnology.

From Nona BioSciences 19 Dec 2023

UMass Amherst researchers develop novel strategy to outsmart antibiotic-resistant ‘superbugs’

Antibiotic-resistant "superbugs" that can defeat efforts to kill them are an urgent public health crisis, and according to the Centers for Disease Control, more than 2.8 million antibiotic-resistant infections occur each year.

18 Dec 2023

UVA atlas unveils cellular blueprint of atherosclerosis

University of Virginia School of Medicine researchers have created an "atlas of atherosclerosis" that reveals, at the level of individual cells, critical processes responsible for forming the harmful plaque buildup that causes heart attacks, strokes and coronary artery disease.

12 Dec 2023

Research uncovers potential treatment target for rare, genetic type of epilepsy

Researchers at the Francis Crick Institute, UCL and MSD have identified a potential treatment target for a genetic type of epilepsy.

11 Dec 2023

Gyros Protein Technologies and Biotage partner to advance peptide purification efficiency with new automated solution

Gyros Protein Technologies AB today announced a partnership with offer Biotage®.

From Gyros Protein Technologies AB 8 Dec 2023

Vanderbilt's potential schizophrenia treatment enters phase 1 clinical trials

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials-;the third WCNDD therapeutic to reach that benchmark.

7 Dec 2023

Refeyn launches KaritroMP for rapid and reproducible characterization of large viral vectors

Refeyn, a leader in mass photometry technology, announces the launch of its macro mass photometry platform, KaritroMP.

From Refeyn 4 Dec 2023

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing

CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH).

From CN-Bio 4 Dec 2023

UK Biobank unveils world's largest genetic data set

In a momentous landmark for medical research, UK Biobank has today [Thursday 30 November] unveiled incredible new data from whole genome sequencing of its half a million participants.

4 Dec 2023

UK Biobank data opens door to new era of precision medicine

In a momentous landmark for medical research, UK Biobank has today [Thursday 30 November] unveiled incredible new data from whole genome sequencing of its half a million participants.

29 Nov 2023

Novel method can detect contaminants in T-cell cultures within 24 hours

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT's research enterprise in Singapore, in collaboration with Singapore Centre for Environmental Life Sciences Engineering (SCELSE) and Massachusetts Institute of Technology (MIT), have developed a novel method capable of identifying contaminants in T-cell cultures within 24 hours.

27 Nov 2023

Almirall and Absci partner to develop AI-designed therapeutics for dermatological diseases

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

20 Nov 2023

Tackling Antimicrobial Resistance Together: A Conversation with Dr. Beverley Isherwood

An interview with Dr Beverley Isherwood.

16 Nov 2023

ATCC announces award from national institute of allergy and infectious diseases to support its preclinical services for biopharmaceutical product development

ATCC today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract.

From ATCC 13 Nov 2023